Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Brian Ingram_2023
VIEWPOINTS

Brian Ingram, Director, Discovery & Translational Sciences at Metabolon Shares his Views on the Expansion of its Inflammation Portfolio

Shots: Brian briefed our readers about Metabolon’s inflammation portfolio expansion with the launch of new Targeted Panels studying cannabinoids, sphingolipids, and lipid mediators of inflammation including its Oxysterols Targeted Panel He also talked about Endocannabinoids and Sphingolipids and how Metabolon targeted panels are used for their measurements The interview highlights how Metabolon’s mission to deliver…
July 6, 2023

Read more

VIEWPOINTS_Michael Irizarry1_2023
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

Shots: Michael spoke about the P-III Clarity AD study evaluating Leqembi (lecanemab) for the treatment of mild cognitive impairment due to Alzheimer’s disease presented at CTAD 2022 He also talked about Eisai’s collaboration with Biogen for the co-commercialization and co-promotion of Lecanemab The interview gives an understanding of how Biogen develops and delivers innovative therapies…
July 4, 2023

Read more

VIEWPOINTS_Dr. Mourad Farouk Rezk1_2023
VIEWPOINTS

Dr. Mourad Farouk Rezk, Head of Global Medical & Development Biogen Biosimilars Shares Insights on Positive P-III Data for BIIB800 (Actemra biosimilar)

Shots : Dr. Mourad talked about the positive P-III data showing results for BIIB800, a Tocilizumab biosimilar candidate presented at the Annual European Congress of Rheumatology (EULAR 2022) He also spoke about the results of the 48-week analysis of the PROPER trial evaluating   adalimumab biosimilar, Imraldi, in patients with autoimmune diseases The interview highlights Biogen's…
June 27, 2023

Read more

VIEWPOINTS_Andrea Mugan_2023
VIEWPOINTS

Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights on ‘Never Miss’ campaign

Shots: Andrea briefed PharmaShots about the global prostate cancer awareness ‘Never Miss’ campaign developed by AstraZeneca and MSD to help men understand their potential risk of developing prostate cancer He also talked about the increasing number of prostate cancer patients and how this campaign will help support those who may be impacted by prostate cancer…
June 22, 2023

Read more

VIEWPOINTS_John Orwin_2023
VIEWPOINTS

John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer

Shots: John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with Xencor He also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platform The interview gives an understanding of Atreca’s focus on…
June 20, 2023

Read more

VIEWPOINTS_Anand Patel_2023
VIEWPOINTS

Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

Shots: Anand briefed PharmaShots about the study design and the results from the RELIEF-DPN-1 trial of its investigational drug LX9211 presented at the 16th Annual Pain Therapeutics Summit He spoke about how LX9211 met its primary endpoints and how the drug shows considerable promise as a novel therapeutic medication for the treatment of painful diabetic…
June 19, 2023

Read more

VIEWPOINTS_Philippe Halfon_2023
VIEWPOINTS

Philippe Halfon, President & Founder of Genoscience Pharma Shares Insights from the P-IIb Trial of Ezurpimtrostat to Treat Hepatocarcinoma

Shots: Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent) He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC alone The interview gives an…
June 15, 2023

Read more

VIEWPOINTS_Rui Avelar_2023
VIEWPOINTS

Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau

Shots: Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeks The data was presented at the 2023 IMCAS World Congress in…
June 13, 2023

Read more

VIEWPOINTS_Avery Ince_2023
VIEWPOINTS

Avery Ince, VP, Medical Affairs – CVM Franchise, Janssen Shares his Views on New Data from P-III VOYAGER PAD Trial

Shots: Avery spoke about the study design and the new data obtained from the P-III VOYAGER PAD trial evaluating Xarelto + Aspirin to treat peripheral artery disease presented at the 72nd ACC 2023 The data demonstrated that the treatment with the Xarelto vascular dose following LER had a 33% reduction in acute limb ischemia and a 15%…
June 5, 2023

Read more

VIEWPOINTS_Anas Batikhi_2023
VIEWPOINTS

Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

Shots: Anas spoke about revenue cycle management in the healthcare sector and the traditional challenges in the healthcare RCM He also elaborated on how the evolving technologies can help to overcome the challenges in healthcare revenue cycle management The interview shows how Santechture is developing smart AI-based and cloud-based solutions to help healthcare providers develop…
June 2, 2023

Read more

Load more